Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals, a biopharmaceutical company engaged in discovery, development and commercialisation of medicines, has reported revenues of $156.1m for the third quarter ended 30 September 2010, compared to $193.92m for the same period in 2009.
Subscribe to our email newsletter
Amylin has posted a net loss of $50.73m for the third quarter 2010, or $0.35 loss per diluted share, compared to net loss of $26.66m, or $0.19 loss per diluted share, for the comparable period in 2009.
Operating loss was $45.03m, compared to $22.4m for the comparable period in 2009.
Amylin has posted a revenue of $494.62m, for the nine months ended 30 September 2010, compared to $572.89m for the year ago period.
For the nine months ended 30 September 2010, Amylin has posted a net income of $133.13m, or $0.93 loss per diluted share, compared to net loss of $135.99, or $0.97 loss per diluted share, for the year ago period.
Operating loss was $116.43m, compared to $126.1m for the year ago period.
Amylin president and CEO Daniel Bradbury said that while disappointed about the complete response letter for Bydureon, they were more committed than ever to working closely with the FDA to bring the drug to people with type 2 diabetes as quickly as possible.
"We are operating from a strong cash position and will continue to drive revenue from Byetta and Symlin and control our expenses in order to deliver strong financial performance for our shareholders," Bradbury said.